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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the efficacy and cost-effectiveness of self-management interventions for adults and children with non-cystic fibrosis bronchiec-
tasis.
B A C K G R O U N D
Description of the condition
Bronchiectasis, also referred to as non-cystic fibrosis (non-CF)
bronchiectasis, is a persistent respiratory condition characterised
by abnormal dilation of the airways (Pasteur 2010; Chang 2015).
Pathological processes include weakness and destruction of the
structural components of the bronchial wall, which together with
the loss of ciliated epithelium, and increase in number and hyper-
trophy of mucus-secreting glands, causes mucus to accumulate,
which in turn creates a conducive environment for bacteria and
leads to a ‘vicious cycle’ of bacterial infection (Cole 1986), in-
flammatory mediator release, airway damage and further infection
(Welsh 2015). Chronic infection is associated with a variety of
pathogens (Martinez-García 2007;Murray 2011; Chalmers 2012;
Tunney 2013), contributing to persistent symptoms and repeated
exacerbations (Murray 2011).
Causes of bronchiectasis include a wide range of factors such as
damage by serious infection (including mycobacterium tubercu-
losis), immune deficiency, allergic bronchopulmonary aspergillo-
sis, and recurrent aspiration, although the majority of cases are
idiopathic (Pasteur 2000; Goeminne 2012). Diagnosis is based on
clinico-radiographic assessments, requiring identification of one
or more abnormally dilated bronchi using high-resolution com-
puterised tomography (HRCT) scanning and appropriate symp-
toms, including chronic productive or wet cough and recurrent
lower respiratory tract infections, together with a range of other
symptoms such as breathlessness, wheeze, chest pains (related to
inflammatory burden) and lethargy (Pasteur 2010; Chang 2015).
Factors associated with disease severity include frequency of hospi-
tal admissions and mortality, poor lung function, bacterial coloni-
sation, high Medical Research Council (MRC) dyspnoea score
and frequency of exacerbations (Chalmers 2014; Martinez-García
2014). The impact on people’s quality of life is significant and
health status is poor with progressive deterioration. Severity may
be assessed with tools such as the Bronchiectasis Severity Index
(Chalmers 2014), or FACED (FEV1, Age, Chronic colonisation,
Extension (number of lobes),Dyspnoea) (Martinez-García 2014),
to identify high-risk individuals, though they have limited value as
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outcome measures because of the non-modifiable nature of com-
ponents such as lung function.
Estimates of the prevalence of bronchiectasis vary considerably.
Although it has previously been considered a relatively rare disease
(Kolbe 1996), more recent studies have suggested an increasing
prevalence, particularly in those over 75 years (Weycker 2005),
and higher prevalence rates in low-income and middle-income
countries (Habesoglu 2011). Co-morbidity may also influence
detection and prevalence, with one UK study showing that 29%
of people with COPD scanned by HRCT had bronchiectasis (
O’Brien 2000). Prevalence rates per 100,000 were estimated at 0.5
in Finland and 3.7 in New Zealand though these data are more
than 10 years old (European Lung White Book 2013). Higher
prevalence rates have been observed in ethnic populations such as
amongst indigenous Australians (up to 14 per 1000) and Native
Alaskan children (up to 20.5 per 1000) (Singleton 2000; Twiss
2005). Higher prevalence rates are also observed in women and
people aged over 60 years (Chang 2003; Seitz 2012). Recent data
suggest that incidence and prevalence in the UK may be higher
than previously estimated (Quint 2016). Over a nine-year period
to 2013, point prevalence rates per 100,000 rose from 350.5 to
566.1 in women and from 301.2 to 485.5 in men. This reflects
an increase of more than 60% with approximately 263,000 adults
living with bronchiectasis in 2013. Similarly, the incidence rates
per 100,000 person-years rose from 21.2 to 35.2 in women and
from 18.2 to 26.9 in men, a 63% increase in new cases to over
15,000 in 2013. However, these increases may be due to improved
diagnosis resulting from easier access to high quality CT scanners,
rather than a true rise in prevalence (Goeminne 2016).
Mortality rates in England andWales rose by 3% per year between
2001 to 2007 (Roberts 2010), and hospitalisations also increased
by 3% per year over a nine-year period in the US (Seitz 2010).
Average mortality rates per 100,000 general population in Europe
are estimated at 0.3 in 27 of the 28 countries in the EU (ranging
from 0.01 in Germany to 1.18 in the UK) and 0.2 in nine non-EU
countries (ranging from 0.01 in Azerbaijan to 0.67 in Kyrgyzstan),
based on 2005 to 2009 data (European Lung White Book 2013).
The recent UK study reported higher age-adjusted mortality rates,
with estimates 2.26 times higher in women and 2.14 times higher
in men compared to the general population (Quint 2016).
The main aims of therapeutic management are: preservation of
lung function, reduction of symptoms and exacerbations, min-
imising complications, and improvement in quality of life (Pasteur
2010; Saleh 2014; Chang 2015).
Description of the intervention
Taylor 2014 describe a taxonomy in which long-term conditions
are diagnosed and brought under control by professionals; there-
after the individual self-manages the condition with support, to
achieve stable maintenance. Self-management support empowers
the person with the condition by enabling them to modify treat-
ment or behaviour, or to seek professional advice and has been
defined as “increasing the capacity, confidence, and efficacy of
the individual” (Kennedy 2013). Self-management interventions
are defined as structured programmes for individuals, designed to
improve self-health behaviours and self-management skills (Lorig
2003). Self-management programmes should ideally include train-
ing with feedback to improve problem solving, decision making,
resource utilisation, formation of patient-provider partnerships,
action planning and self-tailoring (Lorig 2003). People become
more confident at managing their own health and this in turn
supports the development and maintenance of beneficial health
behaviours (Lorig 2003; Bourbeau 2004).
Self-management support is delivered in a range of ways, all of
which aim to equip the individual with knowledge, ability, and
confidence, to take appropriate action. The support can take
the form of specific techniques employed to help people choose
healthy behaviours, but it can also be a fundamental alteration
of the patient-caregiver relationship into a collaborative partner-
ship (de Silva 2011). Interventions can range from individualised
support such as the provision of educational material, to larger
but localised whole system approaches. An example of a whole
system approach involved practitioners trained to offer a range of
resources such as a tool to assess the support needs of patients,
guidebooks on self-management, and a web-based directory of
local self-management resources (Kennedy 2013). There are also
extensive generic programmes such as the ‘Expert Patients Pro-
gramme’ (Department of Health 2001).
Self-management support increasingly includes a mutually agreed
individualised plan which incorporates behavioural elements in-
cluding goal setting and problem solving. Recent work conducted
by the Richmond Group of Charities and The King’s Fund sug-
gests that clients and professionals should co-create a personalised
self-management plan which could include patient and career ed-
ucation, medicines’ management advice and support, use of tele-
care and telehealth to aid self-monitoring, psychological inter-
ventions (e.g. coaching), telephone-based health coaching, symp-
tom management and patient access to their own records (Naylor
2015). Self-management support and interventions can therefore
vary significantly. All approaches aim to enable the individual to
develop the knowledge and confidence to appropriately manage
their long-term condition, and to seek professional support when
needed.
The components of self-management programmes may need to
be condition specific; for example education may be particularly
beneficial for diabetes, but cognitive and behavioural interven-
tions may work well for people with depression (de Silva 2011).
The principal aims of management in bronchiectasis are to main-
tain and improve pulmonary function and to improve quality
of life by reducing symptoms and exacerbations (Pasteur 2010;
Chang 2015). British Thoracic Society guidelines recommend a
range of therapeutic strategies including physiotherapy for air-
way clearance, pulmonary rehabilitation for significant dyspnoea,
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bronchodilators for reversible airflow obstruction and a range of
antibiotic therapy to reduce bacterial load. The latter may include
short-term courses for exacerbations, prophylactic therapy for fre-
quent exacerbators (≥ 3 exacerbations requiring antibiotics per
year) and combination therapy for people with multiple airway
pathogens (Pasteur 2010). Recommendations are often based on
a small number of short trials that are insufficient to draw firm
conclusions about benefits and harms (Welsh 2015).
Bronchiectasis impacts upon physical and psychosocial well-being
and there is the potential to improve self-management through
self-regulation of medication, adherence to airway clearance tech-
niques and patient education about management of the condi-
tion (Lavery 2007). Current guidelines recommend airway clear-
ance techniques, adherence to medication, action plans, exer-
cise (including pulmonary rehabilitation), and patient education
as potential components of self-management interventions for
bronchiectasis (Pasteur 2010;Chang 2015). The educational com-
ponent focuses on understanding the basic principles of disease
management and early recognition of an exacerbation to facilitate
timely intervention (Pasteur 2010). In COPD, self-management
programmes that include action plans have been shown to acceler-
ate appropriate treatment-seeking behaviours (Walters 2010), and
studies including action plans should therefore be considered sep-
arately.
How the intervention might work
Studies of long-term chronic conditions suggest that self-manage-
ment support may improve self-efficacy, health status, psycholog-
ical well-being, coping strategies and physical functioning (Farrell
2004; Griffiths 2005; Siu 2007; Challis 2010). Benefits may be
attributable to enhanced adherence to medication, the adoption
of appropriate behaviours, and reduced stress and anxiety, though
this may also be associated with increased use of healthcare re-
sources (Naylor 2015). Self-management programmes for chronic
obstructive pulmonary disease (COPD), defined as above, have
improved quality of life and reduced breathlessness and hospital
admissions (Zwerink 2014), though there is currently no con-
sensus on the most effective components of self-management in-
terventions (Effing 2012). The evidence of effectiveness in cystic
fibrosis is less clear, with interpretation of observed increases in
knowledge and changes in behaviour hampered by small, poor-
quality trials (Savage 2014).
The objectives of care in bronchiectasis are to treat identifiable
underlying causes, control symptoms, reduce the number of ex-
acerbations, prevent deterioration in pulmonary function, im-
prove quality of life and minimise complications (Chalmers 2016;
Pasteur 2010). The potential benefits from self-management in in-
dividuals with bronchiectasis may include: reduction in symptoms
and subsequent improvement in quality of life; and reduction in
the number and severity of exacerbations, together with potential
reduction in hospital admissions, length of stay, and disease and
health status decline.
Non-adherence to therapy may be a significant problem in
bronchiectasis with up to 50% of people with severe chest in-
fections not completing prescribed courses of antibiotics, other
medicines and airway clearance (McCullough 2014). People who
do not adhere to therapy have a shorter time to first exacerbation
(Haworth 2014); and a higher annual exacerbations rate com-
pared to those who are adherent (McCullough 2014). Similar to
reports from cystic fibrosis (Sawicki 2009), treatment burden may
increase with the emergence of new treatments which may in turn
lead to more problems with adherence. Non-adherence to antibi-
otic therapy and airway clearance procedures may be attributable
to a range of factors including beliefs about their potential risks
and benefits, a younger age and (for antibiotics) a higher number
of prescribed medications (McCullough 2015). It is likely that pa-
tient self-management programmes may help to improve adher-
ence to prescribed therapy and reduce the negative consequences
of poor adherence. With the rise of antimicrobial resistance, ad-
herence to frontline antibiotic therapy may be particularly impor-
tant for people with bronchiectasis (O’Neill 2016).
Why it is important to do this review
Non-CF bronchiectasis is a chronic disease which causes both
persistent day-to-day symptoms such as cough and breathlessness,
and intercurrent exacerbations. The long-term management of
bronchiectasis focuses on reducing these features of the disease.
Self-management interventions have been shown to be benefi-
cial in the management of other airways diseases associated with
management of day-to-day respiratory symptoms and respira-
tory exacerbations such as asthma and COPD (Zwerink 2014;
Peytremann-Bridevaux 2015). Guidelines recommend self-man-
agement plans for these diseases and patient education is one of
the factors in bronchiectasis management recently prioritised by
the European EMBARC group (Aliberti 2016).
This review aims to summarise the evidence for self-management
strategies for people with bronchiectasis and will seek to provide
guidance for both current recommendations and possible future
research needs.
O B J E C T I V E S
To assess the efficacy and cost-effectiveness of self-management
interventions for adults and children with non-cystic fibrosis
bronchiectasis.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We will include parallel and cluster-randomised controlled trials
(RCTs) of any duration. We will include studies reported as full-
text, those published as abstract only, and unpublished data.
Types of participants
Adults (> 18 years) and children with a diagnosis of non-cystic
fibrosis bronchiectasis confirmed by plain film chest radiograph,
bronchography or high-resolution computed tomography with at
least three months of daily sputum expectoration. We will exclude
participants with a diagnosis of cystic fibrosis (CF), sarcoidosis
or active allergic bronchopulmonary aspergillosis. We will also
exclude studies of other long-term health conditions unless results
for people with bronchiectasis are reported separately.
Types of interventions
Self-management interventions are defined as structured interven-
tions for individuals with bronchiectasis designed to improve self-
health behaviours and self-management skills. The interventions
should include collaborative interaction between participants and
healthcare providers, involving goal setting and feedback, with at
least two points of contact. Self-management interventions should
include at least two of the following components: patient ed-
ucation, airway clearance techniques, adherence to medication,
exercise (including pulmonary rehabilitation), and action plans
(Pasteur 2010; Chang 2015). Self-management interventions that
include action plans will be considered separately (Hagger 2014).
We will exclude interventions solely comprising participant edu-
cation or those focused only on exercise, such as pulmonary re-
habilitation delivered in a care setting. We will include studies of
self-management interventions delivered in any form (e.g. Inter-
net, mobile device, face-to-face, paper) with the following com-
parisons.
• Self-management versus usual care.
• Self-management versus an alternate form of self-
management (e.g. paper-based booklet versus mobile app).
For comparisons between different types of self-management we
will include co-interventions, including types of exercise interven-
tions, provided they are evenly distributed between the groups.
Types of outcome measures
We will include all outcomes irrespective of follow-up duration,
but will evaluate the impact of follow-up in sub-group analyses.
Primary outcomes
1. Health-related quality of life using measures validated for
patients with bronchiectasis in a clinical setting (e.g.
Bronchiectasis Severity Index (BSI; St. George’s Respiratory
Questionnaire (SGRQ)).
2. Exacerbations (requiring antibiotic therapy) measured as
frequency, proportion with one or more, or duration.
3. Serious adverse events (i.e. any adverse even that results in
death or is life-threatening).
Secondary outcomes
1. Frequency of hospital admissions measured.
2. Lung function (forced expiratory volume in one second
(FEV ) litres or percent of predicted).
3. Symptoms (e.g. dyspnoea, cough, wheeze), for example
using the Leicester Cough Questionnaire (LCQ).
4. Self-efficacy (e.g. Chronic Disease Self-Efficacy Scale).
5. Economic costs (e.g. direct: costs of care such as cost-
benefit or cost-effectiveness; indirect: days lost from work or full-
time education).
6. Adverse events (e.g. pneumonia).
Reporting of one ormore of the listed outcomes is not an inclusion
criterion for the review.
Search methods for identification of studies
Electronic searches
We will identify studies from the Cochrane Airways Group’s Spe-
cialised Register (CAGR), which is maintained by the Information
Specialist for the Group. The Register contains trial reports identi-
fied through systematic searches of multiple healthcare databases,
and handsearching of respiratory journals and meeting abstracts
(please see Appendix 1 for further details). We will search all
records in the CAGR using the search strategy in Appendix 2.
We will also conduct a search of ClinicalTrials.gov (
www.ClinicalTrials.gov) and the World Health Organization
(WHO) trials portal (www.who.int/ictrp/en/). We will search all
databases from their inception to the present, and we will impose
no restriction on language of publication.
Searching other resources
We will check reference lists of all primary studies and review ar-
ticles for additional references. We will search relevant manufac-
turers’ websites for trial information. We will search the ‘grey’ lit-
erature at OpenGrey (www.opengrey.eu/).
We will search for errata or retractions from included studies pub-
lished in full-text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
and report the date this was done within the review.
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Data collection and analysis
Selection of studies
Two review authors (CK and SG) will independently screen titles
and abstracts for inclusion of all the potential studies we identify
as a result of the search and code them as ’retrieve’ (eligible or
potentially eligible/unclear) or ’do not retrieve’. We will retrieve
the full-text study reports/publication and two review authors (CK
andSG)will independently screen the full-text and identify studies
for inclusion, and identify and record reasons for exclusion of
the ineligible studies. We will resolve any disagreement through
discussion or, if required, we will consult a third review author
(SS). We will identify and exclude duplicates and collate multiple
reports of the same study so that each study rather than each report
is the unit of interest in the review. We will record the selection
process in sufficient detail to complete a PRISMA flow diagram
and a ’Characteristics of excluded studies’ table (Moher 2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data which has been piloted on at least one study in
the review. The following characteristics will be extracted from
included studies by one review author (DL).
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (DL and CK) will independently extract out-
come data from included studies. We will note in the ’Character-
istics of included studies’ table if outcome data were not reported
in a usable way. We will resolve disagreements by consensus or by
involving a third review author (SS). One review author (SS) will
transfer data into the Review Manager 5 file (RevMan 2014). We
will double-check that data is entered correctly by comparing the
data presented in the systematic review with the study reports. A
second review author (CK) will spot-check study characteristics
for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (CK andDL)will independently assess the risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another review author (SS).Wewill assess the risk of bias according
to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or un-
clear and provide a quote from the study report together with a
justification for our judgment in the ’Risk of bias’ table. We will
summarise the risk of bias judgments across different studies for
each of the domains listed.Wewill consider blinding separately for
different key outcomes where necessary (e.g. for unblinded out-
come assessment, risk of bias for all-cause mortality may be very
different than for a patient-reported quality-of-life scale). Where
information on risk of bias relates to unpublished data or corre-
spondence with a trialist, we will note this in the ’Risk of bias’
table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will estimate intervention effects using odds ratios with 95%
confidence intervals (CI) for dichotomous data and mean differ-
ence or standardised mean difference with 95% CI for continuous
data. If standard deviations (SD) are not reported but other mea-
sures of variance around mean differences, such as standard error,
CIs, or P values are reported, we will calculate these according to
Section 7.3 in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). In this review it is likely that dif-
ferent scales may be used to measure the same outcome (for ex-
ample, Bronchiectasis-Quality of Life (B-QoL) and St. George’s
Respiratory Questionnaire (SGRQ)). In this case, we will use the
standardised mean difference (SMD) and its 95% CI, ensuring a
consistent direction of effect by reversing scaling where necessary,
supported by a statement in the text on direction of interpretation.
We will undertake meta-analyses only where this is meaningful i.e.
if the treatments, participants and the underlying clinical question
are similar enough for pooling to make sense.
We will narratively describe skewed data reported as medians and
interquartile ranges.
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Unit of analysis issues
Cross-over trials
Cross-over trials are not appropriate for this intervention as it is
not possible to avoid carry-over of knowledge acquisition from the
first phase. However, if we identify eligible cross-over studies only
data from the first pre-cross-over phase will be included.
Cluster-randomised trials
Large-scale trials are uncommon in bronchiectasis and it is un-
likely that wewill identify eligible RCTs randomising at the level of
group (e.g. by primary care practice). Eligible cluster-randomised
RCTs will be analysed in accordance with methods described in
Section 16.3 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011), using average cluster size and an es-
timate of the intraclass correlation coefficient (ICC) to adjust sam-
ple sizes to the ’effective sample size’.We will combine single RCTs
with cluster-RCTs if the designs and interventions are considered
sufficiently similar and the effect of the intervention is unlikely to
be influenced by the method of randomisation.
Multiple-arm trials
Where multiple trial arms are reported in a single RCT, we will
describe all study groups in the ’Characteristics of included stud-
ies’ table, but only include the analysis arms that meet our review
criteria. If multiple comparisons (e.g. self-management A versus
self-management B versus self-management C versus usual care)
are combined in the same meta-analysis, we will divide the usual
care (control) group by the number of intervention arms to avoid
’double-counting’. Decisions on unit of analysis issues will be de-
scribed in the text.
Dealing with missing data
We will contact investigators of included studies to provide un-
reported data such as missing outcomes, missing data, means or
SDs. We will note differential dropout between study groups and
note reasons for withdrawal. Where a particular outcome includes
substantial loss to follow-up (≥ 50%), we will report this in the
text and mark the data with an asterisk. We will also note reasons
for missing data and differences in missing data between groups
where reported. We will use available cases for data analysis and
will not imputemissing data.Where studies include analyses based
on the imputation of missing values, we will include data at low
risk of bias and report data separately for those at higher risk of
bias in the text of the review. Multiple imputation methods that
include sensitivity analyses pre-specified in published protocols are
considered at low risk of bias (Little 2012; Gewandter 2014). Im-
putation of missing data related to trial outcomes, using methods
such as last observation carried forward, are not considered ap-
propriate. For example, completion of missing data (e.g. relating
to an efficacy outcome) following an intervention-related death
would be inappropriate (Gewandter 2014).
Where missing data are thought to introduce high risk of bias
(substantial loss to follow-up or inappropriate imputation), we
will explore the impact of including such studies in the overall
assessment of results by a sensitivity analysis.
Assessment of heterogeneity
In this review, the specific nature of the intervention, population,
outcomes and methodological quality may vary considerably be-
tween studies. We will assess potential sources of variability be-
tween studies in the following
ways.
1. Clinical variability: we will compare the distribution of
participants, interventions, and outcomes across the included
studies. We will discuss and agree potential clinical heterogeneity
by consensus.
2. Methodological variability: we will compare study designs
and study quality using risk of bias criteria.
3. Statistical heterogeneity (where variability in the effects of
interventions is greater than expected by chance alone): we will
evaluate the statistical significance of heterogeneity using the
Chi² test (P = 0.10 is significant). However, this test may be
unreliable, lacking power to detect important heterogeneity with
few or small studies and the potential to detect clinically
insignificant heterogeneity with large numbers of studies. It is
also possible for trials to show large consistent effects in the face
of significant heterogeneity. Therefore, in addition to assessing
evidence of heterogeneity using the Chi² test as above, we will
also quantify the magnitude of heterogeneity using the ²
(random-effects model only), and I² statistics with the following
interpretation thresholds, based on recommendations in Section
9.5 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011):
i) 0% to 40%: might not be important;
ii) 30% to 60%: may represent moderate heterogeneity;
iii) 50% to 90%: may represent substantial heterogeneity;
iv) 75% to 100%: considerable heterogeneity.
We will report substantial heterogeneity (> 50%) and explore pos-
sible causes by prespecified subgroup analysis.
Assessment of reporting biases
We will compare the results of data from published and unpub-
lished studies as a direct test of publication bias. If there are a suffi-
cient number of studies (10 ormore), wewill explore potential bias
arising from small-study effects using Egger’s method, to test for
asymmetry in funnel plots (Egger 1997). If smaller studies show
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larger intervention effects compared to larger studies, we will eval-
uate potential causes (for example, poor methodological quality;
differences in populations or interventions) and report studies at
high risk of bias in the text of the review.
Data synthesis
Studies will be included in meta-analyses where the study designs,
interventions and outcomes are similar. Where substantial hetero-
geneity (> 50%) is identified we will report outcomes in the text,
giving direction and size of the effect along with the strength of the
evidence (risk of bias). It is likely that included studies will vary
by population, design and outcomes, therefore meta-analysis us-
ing a random-effects model would be most appropriate. However,
where there are few studies or the effects of interventions across
studies are not randomly distributed (for example, with publica-
tion bias), the random-effects model estimates may be unreliable
or biased. It is likely that this review will only include a small
number of low powered studies, therefore we will use a fixed-effect
model and evaluate the impact of model choice using a sensitivity
analysis. We will synthesise and report dichotomous and continu-
ous data separately for a given outcome, should the need arise (e.g.
exacerbation/no exacerbation or exacerbation duration). Where
end-of-study point estimates and change from baseline scores are
reported we will analyse these separately.We will perform the anal-
yses using Review Manager 5 (RevMan) (RevMan 2014).
Summary of findings table
We will create a ’Summary of findings’ table using the following
primary and secondary outcomes: health-related quality of life,
hospital admissions, serious adverse events, exacerbations, lung
function, self-efficacy and economic costs. We will tabulate the
quality of each outcome using the five GRADE criteria (study
limitations, consistency of effect, imprecision, indirectness and
publication bias) (GRADE 2014). We will use methods and rec-
ommendations described in Section 8.5 and Chapter 12 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011), using GRADEpro software (GRADEpro GDT). We will
justify all decisions to down- or up-grade the quality of studies
using footnotes and we will make comments to aid the reader’s
understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Age: adults (> 18 years) versus children.
2. Duration of follow-up (less than 12 months vs 12 months
or longer).
We will use the following outcomes in subgroup analyses.
1. Health-related quality of life.
2. Hospital admissions.
3. Adverse events.
We will use the formal test for subgroup interactions in Review
Manager 5 (RevMan 2014).
Sensitivity analysis
We plan to carry out the following sensitivity analyses.
1. We will exclude studies at high risk of selection bias.
2. Analyses using a random-effects model.
3. Missing data (studies with > 50% or those using
inappropriate imputation).
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group’s Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
CENTRAL (the Cochrane Library) Monthly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
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Bronchiectasis topic search
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
4. kartagener$.mp.
5. (bronchial$ adj3 dilat$).mp.
6. or/1-5
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter (Lefebvre 2011) are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Self Care Explode All
#6 MeSH DESCRIPTOR Education
#7 MeSH DESCRIPTOR Patient Education as Topic
#8 educat*
#9 self-manag*
#10 “self manag*”
#11 self-car* or “self car*”
#12 train* or instruct*
#13 “patient cent*” or patient-cent*
#14 patient-focus* or “patient focus*”
#15 patient-education or “patient education”
#16 “management plan” or management-plan
#17 management* NEAR1 program*
#18 behavior* or behaviour*
#19 disease* NEAR2 management*
#20 self-efficac*
#21 empower*
#22 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21
#23 #4 AND #22
[In search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, bronchiectasis]
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For the review, CK and SG will select studies for inclusion; DL, CK and SS will extract data from the studies and assess the risk of bias;
SS will enter data into RevMan and perform the analyses; SS, CK, DL and SG will draft the final review.
SS has overall responsibility for the review.
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